Five-Element Conformity Assessment: QMS, PMS, Technical Documentation, DoC and Establishment Registration

1. Key takeaways

Ethiopia applies a five-element conformity assessment framework for medical devices, consistent with the recommendations of the International Medical Device Regulators Forum (IMDRF): quality management systems (QMS), post-market surveillance (PMS), technical documentation, the Declaration of Conformity (DoC) and establishment registration. The level of conformity required for each element increases step by step with the risk class: for low-risk devices several elements are generally not submitted before marketing but remain subject to inspection on request, whereas high-risk devices must submit each element and accept on-site verification. Treating the five elements as a single checklist to be ticked is the most common mistake in dossier preparation. The same element is discharged differently at different risk levels — a QMS certificate may be reviewed rather than audited for Class I, while a Class IV manufacturer faces a site visit — and several obligations that are waived from pre-market submission for low-risk devices remain fully enforceable afterwards. Companies therefore need a preparation matrix, not a checklist: one row per element, one column per risk class, with each cell specifying whether the item is submitted, held ready for inspection, or subject to audit.

2. Legal basis

3. Expert insights

Insight 1: the five elements form a scale of intensity, not a binary question of presence or absence. Taking QMS as the example: for Class I and Class A devices, an ISO 13485 conformity certificate is reviewed, and pre-market regulatory audits are usually not required unless the authority considers them necessary to investigate specific safety or regulatory concerns; high-risk devices, by contrast, must undergo on-site verification. The manner in which the same element is fulfilled differs completely across risk levels, so evidence packages must be planned per class rather than copied across a portfolio.

Insight 2: exemption from pre-market submission for low-risk devices does not mean exemption from the obligation. Table 3 of the general guideline provides that the technical documentation of Class I / Class A devices need not be submitted where the device falls within the low-risk notification list, but the manufacturer must still compile it in the format required by EFDA’s registration requirements and make it available on request; PMS and vigilance plans and their implementation reports can likewise be required and reviewed. Not having to submit now and not having to prepare are two different things. Authorities routinely exercise their inspection rights years after notification, so the ready-to-show file must be maintained continuously.

Insight 3: the PMS element carries five mandatory documented procedures. Table 3 lists them: establishing and maintaining a PMS system; recording and assessing adverse event reports; and documenting, maintaining and implementing five procedures — complaint handling, distribution records, mandatory problem and adverse event reporting, field corrective actions, and recalls. These five procedures are precisely where inspectors look for evidence, and missing or undated procedure documents are among the most frequently recorded inspection findings in comparable African regimes.

Insight 4: the DoC is the manufacturer’s single-point commitment to every applicable requirement. Section 7.4 of the general guideline requires the manufacturer to issue a written declaration stating that the requirements of the guideline and related documents are, for the devices covered by the declaration, satisfied in full, and that the declaration must be kept up to date. The DoC is not a one-off document but a living document that moves with the product and its evidence: each substantive change to design, claims or supporting evidence should trigger a review and, where needed, a re-issued declaration with a version history.

Insight 5: the establishment registration element is discharged through the local entity. Because EFDA does not register foreign manufacturers, Section 7.5 requires manufacturers, distributors, importers, wholesalers and authorized representatives to provide sufficient information on premises licensing and device registration requirements before the device is placed on the market. The real carriers of this element are the local agent and the license holder. The foreign manufacturer’s role is to equip them — with documentation, powers and timely information — so that the establishment-level obligations can actually be met.

4. Practical recommendations

1. Build a five-element preparation matrix per risk class, marking each cell as submit / hold-ready / audit.
2. Maintain complete technical documentation even for low-risk devices that need not submit, ready for authority inspection at any time.
3. Document the five PMS procedures in advance: complaints, distribution, reporting, corrective actions, recalls.
4. Bring the DoC under change management: significant changes require re-issue and archived versions.
5. Assign the establishment registration element to the local agent, fixing responsibilities and cooperation duties in the agreement.
6. Keep evidence of QMS certificate validity, since renewals and reviews will both verify it.

5. Verification checklist

• □ Confirmed the manner of fulfilment of each of the five elements per risk class
• □ Compiled the technical documentation (even where submission is not required)
• □ Documented the five PMS procedures
• □ Issued and continuously updated the Declaration of Conformity
• □ Completed establishment registration obligations through the local agent

Regulatory information verified as of October 29, 2026. The five-element framework and the class-specific requirements listed above are based on the current text of Section 7 of EFDA-GDL-046; where the guideline is updated, the information must be re-checked.

• Ethiopia local support: GRZAN assists manufacturers from the Chinese mainland and overseas in dealing with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical dossier preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility assessment, Essential Principles conformity justification, labelling and instructions-for-use localization in English, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.